Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy
M. M. Wyatt, L. W. Huff, M. H. Nelson, L. R. Neal, A. R. Medvec, G. O. Rangel Rivera, A. S. Smith, A. M. Rivera Reyes, H. M. Knochelmann, J. L. Riley, G. B. Lesinski, C. M. Paulos
This study shows that reducing TCR and co-stimulation signal strength in Th17 cell manufacturing enhances their metabolic fitness and antitumor efficacy in mesothelioma models.
bioRxiv · Oct 28, 2022Immunology